Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sidney Goldstein

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Circulation. Heart Failure|December 9, 2017
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of ElamipretideMelissa A Daubert, Eric Yow, Gary Dunn, et al.
Thrombosis and Haemostasis|March 28, 2014
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndromeSidney Goldstein, Eric R Bates, Deepak L Bhatt, et al.
Circulation|December 4, 2002
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failureGeorge Suzuki, Hideaki Morita, Takayuki Mishima, et al.
Cardiovascular Drugs and Therapy|February 13, 2007
Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failureGeorge Suzuki, Sanjaya Khanal, Sharad Rastogi, et al.
Journal of Cardiac Failure|April 29, 2009
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)Jalal K Ghali, John Wikstrand, Dirk J Van Veldhuisen, et al.
British Journal of Pharmacology|January 24, 2003
Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failureGeorge Suzuki, Takayuki Mishima, Elaine J Tanhehco, et al.
American Heart Journal|September 18, 2012
Implications of geographical variation on clinical outcomes of cardiovascular trialsRobert J Mentz, Juan-Carlos Kaski, Gheorghe-Andrei Dan, et al.
International Journal of Cardiology|January 10, 2013
Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challengesFaiez Zannad, Wendy Gattis Stough, Véronique Regnault, et al.
Journal of Cardiac Failure|August 30, 2011
Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureWilliam T Abraham, Koonlawee Nademanee, Kent Volosin, et al.
American Heart Journal|February 15, 2011
A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureAlan Kadish, Koonlawee Nademanee, Kent Volosin, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Circulation. Heart Failure|December 9, 2017
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of ElamipretideMelissa A Daubert, Eric Yow, Gary Dunn, et al.
Thrombosis and Haemostasis|March 28, 2014
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndromeSidney Goldstein, Eric R Bates, Deepak L Bhatt, et al.
Circulation|December 4, 2002
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failureGeorge Suzuki, Hideaki Morita, Takayuki Mishima, et al.
Cardiovascular Drugs and Therapy|February 13, 2007
Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failureGeorge Suzuki, Sanjaya Khanal, Sharad Rastogi, et al.
Journal of Cardiac Failure|April 29, 2009
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)Jalal K Ghali, John Wikstrand, Dirk J Van Veldhuisen, et al.
British Journal of Pharmacology|January 24, 2003
Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failureGeorge Suzuki, Takayuki Mishima, Elaine J Tanhehco, et al.
American Heart Journal|September 18, 2012
Implications of geographical variation on clinical outcomes of cardiovascular trialsRobert J Mentz, Juan-Carlos Kaski, Gheorghe-Andrei Dan, et al.
International Journal of Cardiology|January 10, 2013
Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challengesFaiez Zannad, Wendy Gattis Stough, Véronique Regnault, et al.
Journal of Cardiac Failure|August 30, 2011
Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureWilliam T Abraham, Koonlawee Nademanee, Kent Volosin, et al.
American Heart Journal|February 15, 2011
A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureAlan Kadish, Koonlawee Nademanee, Kent Volosin, et al.
Pageof 5